Sign in
CompletedNo phase

CPI Combination Therapy for Autoimmune Encephalitis

Key facts

Who runs it
Xuanwu Hospital, Beijing
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
70 people enrolled
Started
25 Nov 2020
Ended
12 Sept 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Plasma exchange (PE)
  • intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
Record updated
27 June 2025

Who can take part

Age
14 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • 14-65 years old
  • met all the three following diagnostic criteria of AE: (i) subacute onset (rapid progress of less than 3 months) of working memory deficits, altered mental status, or psychiatric symptoms; (ii) at least one of the followings: new focal CNS findings, seizures not explained by a previously known disease, cerebrospinal fluid (CSF) pleocytosis (white blood cell count 5 cells/mm3), magnetic resonance imaging (MRI) features suggestive of encephalitis, and (iii) reasonable exclusion of alternative causes
  • the presence of antibody against neuronal surface antigen in serum or CSF indicating a positive diagnosis of AE using a cell-based assay
  • critically ill with a modified Rankin scale (mRS) score of 4 to 5
  • within 3 months of onset
  • no immunotherapy previously

Who cannot take part

  • relative contraindications of TPE treatment: serious underlying diseases such as severe active hemorrhage, disseminated intravascular coagulation, severe hypotension or shock, unstable cardiac failure, cerebral herniation, severe infection or other endangered conditions
  • allergic to immunoglobulin
  • contraindications of glucocorticoid therapy: glucocorticoid allergy, active gastric or duodenal ulcer, severe osteoporosis, diabetes, hypertension after recent gastrointestinal anastomosis, and serious infection that cannot be controlled by antibiotics
  • serious underlying diseases, such as cardiac dysfunction, arrhythmia, and coagulation disorders
  • premorbid mRS ≥ 3

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange (PE) are the first-line therapies for autoimmune encephalitis (AE) patients, but optimal first-line treatment strategy for different AE patients remains undetermined. The study is to compare the efficacy between pulse corticosteroid plus PE initially followed by IVIG (CPI therapy) and pulse corticosteroid plus IVIG followed by PE two weeks later (CIP therapy) in patients with severe antibody-associated autoimmune encephalitis (AE).

The 2 groups in the trial

  • CPI groupTreatment being tested

    Intravenous methylprednisolone (IVMP) combined with PE (5 times in each course) and IVIG after PE.

    Treatment: Plasma exchange (PE) and intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)

  • CIP groupExisting treatment, for comparison

    IVMP and IVIG (0.4g/kg/d for 5 days) immediately, followed by PE at least 2 weeks after IVIG treatment.

    Treatment: Plasma exchange (PE) and intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Combination Therapy of Pulse Corticosteroid and Plasma Exchange Followed by Intravenous Immunoglobulin in Patients With Severe Antibody- Associated Autoimmune Encephalitis: a Randomized Controlled Trial
Record updated
27 June 2025